Neo-Concept International Group Holdings Limited
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Yuk Yin Siu
- Full Time Employees
- 24
- Sector
- Consumer Cyclical
- Industry
- Apparel - Manufacturers
- Address
- Seaview Centre Kwun Tong Hong Kong
- IPO Date
- Apr 23, 2024
- CIK
- 0001916331
- Website
- neo-ig.com
- Similar Companies
- Business
- Neo-Concept International Group Holdings Limited (NCI) designs, markets, and distributes fashion apparel, footwear, and accessories primarily under its own brands. The company offers a diverse portfolio of products including women's and men's clothing such as dresses, tops, bottoms, and outerwear; footwear ranging from casual sneakers to formal heels; and accessories like handbags, jewelry, belts, and hats; all targeted at mid-market consumers seeking trendy, affordable fashion. Operating through wholesale, retail, and e-commerce channels, NCI serves department stores, specialty retailers, and online platforms in key markets across Asia, North America, and Europe. Founded in 2002 and headquartered in Hong Kong, the company maintains manufacturing facilities and sourcing networks predominantly in China, Vietnam, and Bangladesh to support its global supply chain. Its business segments encompass brand management, product development, and international distribution, with a focus on fast-fashion cycles and private-label services for select partners. Subsidiaries include operational units handling design studios in Hong Kong and sales offices in the United States and Europe, enabling localized market penetration. In recent developments, Neo-Concept expanded its footprint through a strategic partnership with a major U.S. department store chain in early 2025, enhancing distribution for its flagship footwear line. The company also completed a HK$150 million funding round in mid-2024 led by institutional investors, earmarked for e-commerce platform upgrades and entry into sustainable apparel initiatives. Additionally, NCI launched a new eco-friendly accessories collection under the "Neo-Green" sub-brand in late 2024, marking its shift toward environmentally conscious products amid growing consumer demand.
Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026
Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer
NTG Clarity Networks Inc. (NCI:CA) Q1 2026 Earnings Call Transcript
ImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory for the Tokyo Strain of BCG to Enhance BCG Supply in the United States
Neo-Concept International Announces Share Consolidation
NTG Clarity Networks Inc. (NCI:CA) Q4 2025 Earnings Call Transcript
Rosen Law Firm Encourages Neo-Concept International Group Holdings Ltd. Investors to Inquire About Securities Class Action Investigation – NCI
Rosen Law Firm Encourages Neo-Concept International Group Holdings Ltd. Investors to Inquire About Securities Class Action Investigation – NCI
Reliance Industries to Fund $300B US Refinery: India ETFs in Focus
D. Boral Capital Acted as Lead Placement Agent to Neo-Concept International Group Holdings Limited (Nasdaq:NCI) in Connection with its ~$8,000,000 Follow-On Offering
Neo-Concept International Group Holdings Limited Announces Closing of Approximately US$8.1 Million Public Offering of Class A Ordinary Shares
Neo-Concept International Group Holdings Limited Announces Pricing of Approximately US$8.1 Million Public Offering of Class A Ordinary Shares
Neo-Concept International Group Holdings Limited Announces First Half 2025 Unaudited Financial Results
NTG Clarity Networks Inc. (NCI:CA) Q3 2025 Earnings Call Transcript
Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3Kα Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducing Hyperglycemia
Cogent Biosciences Announces KRAS Poster Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
BBOT Presents Preclinical Data Demonstrating Potential of BBO-11818 as a Potent panKRAS Inhibitor at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
I-Mab To Present Positive Updated Givastomig Monotherapy Data at 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 23, 2025
Repare Therapeutics to Present Initial Data from Phase 1 LIONS Clinical Trial at 37th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+™ in Prostate Cancer